Search results
If You'd Invested $1,000 in Moderna Stock 5 Years Ago, Here's How Much You'd Have Today
Motley Fool via Yahoo Finance· 7 days agoFive years ago, pharmaceutical company Moderna (NASDAQ: MRNA) was mostly unknown. It was developing...
Moderna Stock Rebounds From Its RSV Vaccine Fallout — Is It A Buy, Again?
Investor's Business Daily· 2 days agoThe cancer vaccine reduced the likelihood cancer would return or patients would die by 49% after...
Moderna Announces Update on Investigational RSV Vaccine
Morningstar· 6 days agoThe FDA has informed Moderna that it is working to conclude...
US FDA pushes decision on Moderna's RSV vaccine to end of this month
Reuters via AOL· 6 days agoThe Food and Drug Administration's move prolongs the wait for Moderna's second approved product, but...
There might be stockpiles, but making an effective bird flu vaccine won’t be quick or easy
The Telegraph via Yahoo News· 2 days agoHealth officials have been steadfast in their assurances. The risk of H5N1 bird flu jumping into...
Will your last COVID vaccine work against new ‘FLiRT’ variants?
WJZY via Yahoo News· 4 days agoIn February, a federal immunization committee voted...the CDC says. Previously, health officials...
Genetics Played Role in Blood Clots Linked to COVID-19 Shots
Time Magazine· 8 hours agoAdenovirus-based vaccines, like the J&J and AstraZeneca shots that were later pulled from the...
Moderna to Present at Upcoming Conferences in May/June 2024
The Sacramento Bee· 3 days agoModerna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences:
The AstraZeneca vaccine – should you be worried?
The Telegraph via Yahoo News· 5 days agoEarlier this week, the European Commission announced that the Covid-19 vaccine, developed as part of a collaboration between the British pharma company...
Is Novavax Stock A Buy After Nearly Tripling On $1.3 Billion Sanofi Deal?
Investor's Business Daily· 2 days agoThe deal is a negative for Covid vaccine rivals Pfizer and Moderna, Leerink Partners analyst David...